SWOG clinical trial number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

15% Accrual
Accrual
15%
Open
Phase
15% Accrual
Accrual
15%
Abbreviated Title
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor…
Status Notes
This study is open to patient accrual effective 10/30/23.
Activated
10/30/2023
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Breast Cancer
Symptom Control and Quality of Life

Treatment

durvalumab

Reports & Approvals

Trial Locations

Other Clinical Trials

S2205
SWOG Clinical Trial Number

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy

Research Committee(s)
Symptom Control and Quality of Life
Activated
03/16/2023
42% Accrual
Accrual
42%
Open
Phase
EAQ202
SWOG Clinical Trial Number

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Research Committee(s)
Symptom Control and Quality of Life
Activated
10/28/2021
Open
Phase
S2013
SWOG Clinical Trial Number

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Research Committee(s)
Symptom Control and Quality of Life
Activated
08/16/2021
60% Accrual
Accrual
60%
Open
Phase